HUP0200103A2 - Eljárás vírus-inaktivált humán gamma-globulin G előállítására - Google Patents

Eljárás vírus-inaktivált humán gamma-globulin G előállítására

Info

Publication number
HUP0200103A2
HUP0200103A2 HU0200103A HUP0200103A HUP0200103A2 HU P0200103 A2 HUP0200103 A2 HU P0200103A2 HU 0200103 A HU0200103 A HU 0200103A HU P0200103 A HUP0200103 A HU P0200103A HU P0200103 A2 HUP0200103 A2 HU P0200103A2
Authority
HU
Hungary
Prior art keywords
virus
followed
peg
production
inactivated human
Prior art date
Application number
HU0200103A
Other languages
English (en)
Inventor
Teresa López Hernández
Francisco Rabaneda Giménez
Pere Ristol Debart
Original Assignee
Probitas Pharma, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probitas Pharma, S.A. filed Critical Probitas Pharma, S.A.
Publication of HU0200103D0 publication Critical patent/HU0200103D0/hu
Publication of HUP0200103A2 publication Critical patent/HUP0200103A2/hu
Publication of HUP0200103A3 publication Critical patent/HUP0200103A3/hu
Publication of HU228252B1 publication Critical patent/HU228252B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A találmány tárgya eljárás vírus-inaktivált humán gamma-globulin Gelőállítására, amely szerint a gamma-globulint etanollal történőfrakcionálással elválasztott frakcióból extrahálják szénhidrátjelenlétében, majd PEG-gel csökkentik a szennyeződések mennyiségét,felviszik egy anioncserélő oszlopra, egy elfolyó folyadékot kapnak,amelynek PEG-tartalmát ezt követően ultraszűréssel csökkentik és afolyadékot betöményítik. Ezután egymást követően egy opcionáliskezelést végeznek savas pH-n, majd legalább egy vírus-inaktiválólépést, amely pasztőrözésből és oldószer/detergens eleggyel valókezelésből áll, ezután a terméket kicsapják és PEG-gel mossák, hogyeltávolítsák a kémiai vírus-inaktiváló reagenseket, majdszolubilizálással és a pH-t megváltoztatva a fehérje szennyeződéseketis, végül ultraszűréssel tisztítják, majd adott esetben vírusszűrésthajtanak végre és ezután 5% vagy 10% fehérje értékre valóbetöményítést végeznek. Ó
HU0200103A 2001-01-17 2002-01-10 Process for the production of virus-inactivated human gammaglobulin g HU228252B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100101A ES2184594B1 (es) 2001-01-17 2001-01-17 Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.

Publications (4)

Publication Number Publication Date
HU0200103D0 HU0200103D0 (en) 2002-03-28
HUP0200103A2 true HUP0200103A2 (hu) 2003-08-28
HUP0200103A3 HUP0200103A3 (en) 2004-10-28
HU228252B1 HU228252B1 (en) 2013-02-28

Family

ID=8496419

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200103A HU228252B1 (en) 2001-01-17 2002-01-10 Process for the production of virus-inactivated human gammaglobulin g

Country Status (14)

Country Link
US (1) US6875848B2 (hu)
EP (1) EP1225180B1 (hu)
JP (1) JP4070468B2 (hu)
AR (1) AR032242A1 (hu)
AT (1) ATE382631T1 (hu)
CZ (1) CZ300413B6 (hu)
DE (1) DE60224310T2 (hu)
ES (2) ES2184594B1 (hu)
HK (1) HK1048324B (hu)
HU (1) HU228252B1 (hu)
MX (1) MXPA02000639A (hu)
PT (1) PT1225180E (hu)
SK (1) SK287633B6 (hu)
UY (1) UY27126A1 (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003262087B2 (en) 2002-09-11 2010-11-11 Chugai Seiyaku Kabushiki Kaisha Protein purification method
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
AU2005229674B2 (en) * 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
US20070049732A1 (en) * 2005-09-01 2007-03-01 Zurlo Eugene J Ultra-high yield intravenous immune globulin preparation
US8293242B2 (en) * 2005-09-01 2012-10-23 Plasma Technologies, Llc Ultra-high yield of alpha-1-anti-trypsin
US7879332B2 (en) * 2005-09-01 2011-02-01 Plasma Technologies, Llc Ultra-high yield intravenous immune globulin preparation
JP2008094722A (ja) * 2006-10-05 2008-04-24 Benesis Corp 免疫グロブリン製剤の製造方法
US20080214795A1 (en) * 2007-02-14 2008-09-04 Amgen Inc. Method of isolating antibodies by precipitation
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US10662237B2 (en) 2009-08-06 2020-05-26 Genentech, Inc. Method to improve virus filtration capacity
EP2477603B1 (en) 2009-09-17 2016-03-30 Baxalta Incorporated Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
RU2558367C2 (ru) * 2010-03-10 2015-08-10 Ф. Хоффманн-Ля Рош Аг Способ очистки полипептидных растворов
US20130172536A1 (en) * 2011-08-16 2013-07-04 Shenzhen Weiguang Biological Products Co.,Ltd. Intravenous Cytomegalovirus Human Immune Globulin and Manufacturing Method Thereof
ES2381828B1 (es) * 2012-03-20 2012-11-16 Grifols, S.A. PROCEDIMIENTO PARA OBTENER UNA COMPOSICION DE IgG MEDIANTE TRATAMIENTO TERMICO
EP3131589B1 (en) 2014-04-15 2023-05-17 Boehringer Ingelheim International GmbH Method and use for continuously inactivating a virus during manufacture of a biological product
EP3154597B1 (en) * 2014-06-12 2019-01-30 Biosyn Arzneimittel GmbH Preparation methods for a novel generation of biological safe klh products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents
CA2951735C (en) 2014-06-12 2020-06-30 Biosyn Arzneimittel Gmbh Preparation methods for a novel generation of biological safe klh products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents
JP6521351B2 (ja) 2014-10-14 2019-05-29 テックプロジェクトサービス株式会社 ウィルス不活化およびサンプリング装置
MX2017005148A (es) 2014-11-06 2017-08-08 Hoffmann La Roche Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.
PL3135687T3 (pl) 2015-08-31 2019-09-30 Instituto Grifols, S.A. Sposób wytwarzania immunoglobulin
KR20180101583A (ko) 2016-02-03 2018-09-12 플라즈마 테크놀로지스, 엘엘씨 혈액 기반 물질로부터 단백질을 추출하기 위한 방법(methods for extracting proteins from a blood-based material)
SG11201807824UA (en) 2016-03-11 2018-10-30 Boehringer Ingelheim Int Methods for continuously inactivating a virus during manufacture of a protein
KR102372105B1 (ko) * 2016-09-26 2022-03-07 인스티투토 그리폴스, 에스.아. 면역글로블린의 제조방법
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
US10815270B1 (en) 2019-09-20 2020-10-27 Plasma Technologies, Llc Compositions and methods for high efficiency protein precipitation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164495A (en) * 1976-04-06 1979-08-14 Nordisk Insulinlaboratorium Method of recovering immunoglobulin using a polyol and an alkanoic acid
US4374763A (en) * 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
EP0116571B2 (en) * 1982-08-30 1997-10-29 BAXTER INTERNATIONAL INC. (a Delaware corporation) Method for making gamma globulin-containing compositions
US5234685A (en) * 1983-03-16 1993-08-10 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Method of determining incompatibility-reaction-causing substances in blood products as well as a method of inactivating said incompatibility-reaction-causing substances
JP2547556B2 (ja) * 1987-02-06 1996-10-23 株式会社 ミドリ十字 ｒ−グロブリンの液状製剤
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
DK0659767T4 (da) * 1993-12-27 2003-02-10 Zlb Bioplasma Ag Fremgangsmåde til fremstilling af et koncentrat af anti-D-immunoglobulin G og et farmaceutisk præparat, som indeholder dette
CA2232420A1 (en) * 1997-03-19 1998-09-19 The Green Cross Corporation Immunoglobulin preparation and preparation process thereof
IL121900A (en) * 1997-10-07 2001-12-23 Omrix Biopharmaceuticals Ltd A method for the purification of immunoglobulins
CN1520885A (zh) * 1997-10-23 2004-08-18 ������ҩ��ʽ���� 可室温贮存的免疫球蛋白静脉注射制剂
UA64742C2 (uk) * 1997-12-24 2004-03-15 Альфа Терапевтик Корпорейшн СПОСІБ ОДЕРЖАННЯ РОЗЧИНУ <font face="Symbol">g</font>-ГЛОБУЛІНУ, ПРИЗНАЧЕНОГО ДЛЯ ВНУТРІШНЬОВЕННОГО ВВЕДЕННЯ, І ПРОДУКТ, ЩО ОДЕРЖУЄТЬСЯ У ЦЕЙ СПОСІБ (ВАРІАНТИ)
US6281336B1 (en) * 1998-06-09 2001-08-28 Statens Serum Institut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
PL196770B1 (pl) * 1998-06-09 2008-01-31 Statens Seruminstitut Sposób oczyszczania immunoglobuliny, produkt immunoglobuliny i jego zastosowanie
US6441144B1 (en) * 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration

Also Published As

Publication number Publication date
HU228252B1 (en) 2013-02-28
ES2295308T3 (es) 2008-04-16
EP1225180A3 (en) 2004-01-28
EP1225180B1 (en) 2008-01-02
HK1048324B (zh) 2008-02-22
MXPA02000639A (es) 2004-11-01
SK582002A3 (en) 2002-10-08
UY27126A1 (es) 2002-07-31
US20020151688A1 (en) 2002-10-17
HK1048324A1 (en) 2003-03-28
PT1225180E (pt) 2008-03-18
DE60224310D1 (de) 2008-02-14
SK287633B6 (sk) 2011-04-05
DE60224310T2 (de) 2009-01-08
US6875848B2 (en) 2005-04-05
HU0200103D0 (en) 2002-03-28
CZ300413B6 (cs) 2009-05-13
ES2184594B1 (es) 2004-01-01
ES2184594A1 (es) 2003-04-01
EP1225180A2 (en) 2002-07-24
JP2003002896A (ja) 2003-01-08
CZ2002131A3 (cs) 2002-09-11
HUP0200103A3 (en) 2004-10-28
AR032242A1 (es) 2003-10-29
JP4070468B2 (ja) 2008-04-02
ATE382631T1 (de) 2008-01-15

Similar Documents

Publication Publication Date Title
HUP0200103A2 (hu) Eljárás vírus-inaktivált humán gamma-globulin G előállítására
WO2003042654A3 (en) Multi-parameter high throughput screening assays (mphts)
ATE211129T1 (de) Inhibitoren von beta-amyloid-protein-herstellung
ATE361067T1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer&#39;s und verbundenen neurodegenerativen erkrankungen
ATE377657T1 (de) Serpin-arzneistoffe zur behandlung einer hiv- infektion und verfahren zu deren verwendung
WO2004024866A3 (en) Protein purification
DE602004016729D1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
DE60330146D1 (de) Verfahren zur reinigung von fibrinogen
ATE352569T1 (de) Verfahren zur abtrennung des alpha-1-proteinase inhibitors von einer cohn-paste, welche die fraktionen iv-1 + iv-4 enthält
HUP0203963A2 (hu) Többlépcsős eljárás pektin és pektincukrok/-oligomerek szimultán tisztítására és elválasztására cukorrépavelőből vizes oldatban
CA2161804A1 (en) Purification of plasma proteins
DE10295664D2 (de) Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Paptide und deren Verwendungen
DE602005002461D1 (de) Einen nanofiltrationsschritt umfassendes verfahren zur aufreinigung von albumin, lösung und zusammensetzung zur therapeutischen anwendung, die dieses enthalten
ATE435026T1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE306564T1 (de) Verfahren zur aufreinigung von maltose
ATE358666T1 (de) Verfahren zur reinigung von dimethylacetamid (dmac)
HUP0302530A2 (hu) Eljárás 2-nitro-4-metilszulfonil-benzoesav tisztítására
DE60034117D1 (de) Verfahren zur herstelllung von gonadotropin-zusammensetzungen
DE3686390D1 (de) Verfahren zur herstellung vom antihaemophilfaktor (ahf) durch kaeltefaellung und zur verbesserung der loeslichkeit des hergestellten ahf-produktes.
ATE204759T1 (de) Verwendung von hyperforin und hyperforinhaltigen extrakten zur behandlung und prophylaxe von demenzerkrankungen
DE69820580D1 (de) Verfahren zur Abtrennung von Metallen durch micellare Ultrafiltration, geeignet zur Behandlung von radioaktiven Abfallstoffen
DE60028538D1 (de) Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
WO2004005882A3 (en) Multi-parameter high throughput screening assays (mphts)
HUP0101995A2 (hu) Eljárás biológiai eredetű, szilárd anyagokat tartalmazó, vizes áramok kezelésére
ATE236876T1 (de) Verfahren zur behandlung von laktamen und verfahren zur laktamreinigung

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: GRIFOLS, S.A., ES

Free format text: FORMER OWNER(S): PROBITAS PHARMA, S.A., ES; GRIFOLS, S.A., ES